Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Mol Cancer Res. 2020 Nov 5;19(2):249–260. doi: 10.1158/1541-7786.MCR-20-0466

Figure 3.

Figure 3.

Cytotoxicity and proteomic effects of a BET inhibitor INCB057643 in DLBCL/HGBCL cell lines with MYC rearrangement or Myc overexpression and with or without TP53 mutation. A total of 8 DLBCL/HGBCL cell lines were selected for study, including 4 Wt-TP53 (OCI-LY10, OCI-LY19, MCA, RC) and 4 Mut-TP53 (GR, HBL1, MZ, and TMD8) cell lines. A, Cell viability of lymphoma cells was significantly inhibited after exposure with INCB057643 for 72 hours using CellTiter-Glo 2.0 Assay. B, IC50 values of INCB057643 in 8 DLBCL/HGBCL cell lines as calculated by GraphPad Prism 8. C, Percentage of apoptotic cells by Annexin V/PI double staining flow cytometry analysis after treatment with INCB057643 for 48 hours. Values indicate mean ± SD for at least three independent experiments performed in triplicate. D, Heatmaps illustrating significantly increased or decreased protein expression measured by the RPPA assays after INCB057643 treatment (2.5 μmol/L for 24 hours) in RC and TMD8 cell lines. E, Venn diagrams (right) illustrate the common and unique modulations in three evaluated cell lines (OCI-LY19, RC, and TMD8). RPPA assays were performed for three independent experiments.